Cancer treatment developer Polaris Group (北極星藥業集團) yesterday said it has no plans to exit the nation’s capital markets, even though the local investment environment is becoming increasingly unfavorable to the biotechnology sector.
The comments came after two biotechnology firms announced their plans to delist from the Taipei Exchange’s Emerging Stock Board earlier this month.
Polaris Group is fully focused on developing its product pipeline and its operation is not affected by its peers’ decisions, Polaris Group chief executive officer Wu Bor-wen (吳伯文) told an investors’ conference.
“Delisting from the local capital markets seems to have become fashionable recently, but we have no plans to follow suit,” Wu said.
Confidence in the local biotechnology sector has been waning, as investors have been rocked by a lack of disclosure by companies, as well as extreme volatility in stock prices, Wu said.
Investors should be aware that developers of new drugs can incur lengthy periods of losses during clinical trials before new products gain regulatory approval for commercialization, Wu said
Such developers often cannot provide monthly updates as clinical trials are ongoing, he said, adding that many firms lack the resources to respond to investors’ questions and concerns.
The investor relations department at Polaris Group has been occupied with clarifying concerns from misleading reports and fake news, Wu said.
The company has also made every effort to pacify emotional outbursts over its share price, he added.
The company reported a net loss of NT$421 million (US$14.02 million) for the first half of this year, an improvement from the previous year’s net loss of NT$511 million. Losses per share were NT$2.04.
Gogoro Inc (睿能創意) yesterday launched its first electric bicycle, the Gogoro Eeyo 1, in Taiwan, after unveiling the bike in New York in late May and in France on Tuesday. The company said it would also introduce the series in other European countries such as Germany and the Netherlands. The “Eeyo project” is the fourth of Gogoro’s eight projects that concentrate on smart transportation, which includes Gogoro’s electric scooter, battery swap system and electric scooter sharing service, company founder and chief executive officer Horace Luke (陸學森) told a media briefing in Taipei. “There are various types of city commuters. We will not
EXPERIMENTAL DRUG: While news about a COVID-19 vaccine is more eye-catching, developing a treatment would be more viable, the Senhwa boss said Senhwa Biosciences Inc (生華科) aims to raise NT$1.5 billion (US$50.57 million) by issuing 15 million new common shares in the third quarter of this year to fund the research of new drugs, including the experimental drug Silmitasertib for the treatment of COVID-19, the company said on Monday. That would be the firm’s largest fundraising effort after it raised more than NT$1.4 billion from an initial public offering on the Taipei Exchange (TPEX) in April 2017, chief financial officer Sarah Chang (張小萍) told the Taipei Times by telephone. The price of the new shares would depend on the firm’s average share price
NOT A PANACEA: Offering 5G services would not solve the problem of declining telecom incomes, chairman Sheih Chi-mau said, expecting a flat 5G telecom revenue Chunghwa Telecom Co (中華電信) yesterday became the nation’s first telecom to debut its 5G services, offering tiered tariffs that include a threshold of NT$599 and flat rates, as it aims to switch half of its subscribers to the 5G network within three years. Subscribers would have unlimited data transmission for monthly fees starting at NT$1,399 — the same flat rate as when the company launched its 4G service in 2014 — and they can subscribe to the highest-rate plan for NT$2,699 per month for faster data transmission speeds and larger bandwidth, the company said. Data transmission speeds would be within the range
STAYING AHEAD: TSMC expects its sales this year to grow 14 to 19 percent and could spend up to US$3.52 billion on research and development, leaving its rivals far behind Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) reported that the US last year approved 99 percent of its patent applications, which placed the tech giant among the top patent holders in the US. In its Corporate Social Responsibility Report, TSMC said it last year secured about 3,600 patents worldwide, including more than 2,300 in the US. As of the end of last year, TSMC owned more than 39,000 patents, the report said. The company last year filed almost 6,500 patent applications worldwide and ranked among the top 10 patent applicants in the US. In Taiwan, it was the largest patent applicant for the fourth